Impact of inflammation-mediated response on pan-coronary plaque vulnerability, myocardial viability and ventricular remodeling in the postinfarction period - the VIABILITY study: Protocol for a non-randomized prospective clinical study.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
entrez:
28
4
2019
pubmed:
28
4
2019
medline:
29
5
2019
Statut:
ppublish
Résumé
While the role of inflammation in acute coronary events is well established, the impact of inflammatory-mediated vulnerability of coronary plaques from the entire coronary tree, on the extension of ventricular remodeling and scaring, has not been clarified yet. The present manuscript describes the procedures of the VIABILITY trial, a descriptive prospective single-center cohort study. The main purpose of this trial is to assess the link between systemic inflammation, pan-coronary plaque vulnerability (referring to the plaque vulnerability within the entire coronary tree), myocardial viability and ventricular remodeling in patients who had suffered a recent ST-segment elevation acute myocardial infarction (STEMI). One hundred patients with STEMI who underwent successful revascularization of the culprit lesion in the first 12 hours after the onset of symptoms will be enrolled in the study. The level of systemic inflammation will be evaluated based on the serum biomarker levels (hs-CRP, matrix metalloproteinases, interleukin-6) in the acute phase of the myocardial infarction (MI) and at 1 month. Pan-coronary plaque vulnerability will be assessed based on serum biomarkers known to be associated with increased plaque vulnerability (V-CAM or I-CAM) and at 1 month after infarction, based on computed tomographic angiography analysis of vulnerability features of all coronary plaques. Myocardial viability and remodeling will be assessed based on 3D speckle tracking echocardiography associated with dobutamine infusion and LGE-CMR associated with post-processing imaging methods. The study population will be categorized in 2 subgroups: subgroup 1 - subjects with STEMI and increased inflammatory response at 7 days after the acute event (hs-CRP ≥ 3 mg/dl), and subgroup 2 - subjects with STEMI and no increased inflammatory response at 7 days (hs-CRP < 3 mg/dl). Study outcomes will consist in the rate of post-infarction heart failure development and the major adverse events (MACE) rate. VIABILITY is the first prospective study designed to evaluate the influence of infarct-related inflammatory response on several major determinants of post-infarction outcomes, such as coronary plaque vulnerability, myocardial viability, and ventricular remodeling.
Identifiants
pubmed: 31027064
doi: 10.1097/MD.0000000000015194
pii: 00005792-201904260-00015
pmc: PMC6831282
doi:
Substances chimiques
Biomarkers
0
Types de publication
Clinical Trial
Clinical Trial Protocol
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15194Références
Gerber Y, Weston SA, Enrique-Sarano M, et al. Mortality associated with heart failure after myocardial infarction: a contemporary community perspective. Circ Heart Fail 2016;9:e002460.
Roger VL. Myocardial infarction outcomes: “the times, they are a-changin...”. Circ Cardiovasc Qual Outcomes 2010;3:568–70.
Benedek I, Gyongyosi M, Benedek T. A prospective regional registry of ST-elevation myocardial infarction in Central Romania: impact of the Stent for Life Initiative recommendations on patient outcomes. Am Heart J 2013;166:457–65.
Benedek I. A new definition of acute myocardial infarction – changing perspectives in acute cardiac care. J Cardiovasc Emerg 2018;4:167–9.
Cahill TJ, Kharbanda RK. Heart failure after myocardial infarction in the era of primary percutaneous coronary intervention: mechanisms, incidence and identification of patients at risk. World J Cardiol 2017;9:407–15.
Kelly DJ, Gershlick T, Witzenbichler B, et al. Incidence and predictors of heart failure following percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI trial. Am Heart J 2011;162:663–70.
Lewis EF, Velazquez EJ, Solomon SD, et al. Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study. Eur Heart J 2008;29:748–56.
Ong SB, Hernández-Reséndiz S, Crespo-Avilan GE, et al. Inflammation following acute myocardial infarction: Multiple players, dynamic roles, and novel therapeutic opportunities. Pharmacol Ther 2018;186:73–87.
Seropian IM, Toldo S, Van Tassell BW, et al. Anti-inflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction. J Am Coll Cardiol 2014;63:1593–603.
Niccoli G, Burzotta F, Galiuto L, et al. Myocardial no-reflow in humans. J Am Coll Cardiol 2009;54:281–92.
Braunwald E. Heart failure. JACC Heart Fail 2013;1:1–20.
Heusch G, Gersh BJ. The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge. Eur Heart J 2017;38:774–84.
Rezkalla SH, Stankowski RV, Hanna J, et al. Management of No-Reflow Phenomen in the Catheterization Laboratory. JACC 2017;10:215–23.
Bouleti C, Mewton N, Germain S. The no-reflow phenomenon: state of the art. Arch Cardiovasc Dis 2015;108:661–74.
Ndrepepa G, Tiroch K, Fusaro M, et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol 2010;55:2383–9.
Kurtul A, Yarlioglues M, Celik IE, et al. Association of lymphocyte-to-monocyte ratio with the no-reflow phenomenon in patients who underwent a primary percutaneous coronary intervention for ST-elevation myocardial infarction. Coron Artery Dis 2015;26:706–12.
Hansson GK, Libby P, Tabas I. Inflammation and plaque vulnerability. J Intern Med 2015;278:483–93.
Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011;473:317–25.
Kataoka Y, Puri R, Nicholls SJ. Inflammation, plaque progression and vulnerability: evidence from intravascular ultrasound imaging. Cardiovasc Diagn Ther 2015;5:280–9.
Stefanadis C, Antoniou CK, Tsiachris D, et al. Coronary atherosclerotic vulnerable plaque: current perspectives. J Am Heart Assoc 2017;6:e005543.
Morariu M, Marton E, Mester A, et al. Association between acute inflammatory response and infarct size in STEMI patients undergoing primary PCI. J Cardiovasc Emerg 2018;4:140–6.
Kelly CR, Weisz G, Maehara A, et al. Relation of C-reactive protein levels to instability of untreated vulnerable coronary plaques (from the PROSPECT Study). Am J Cardiol 2014;114:376–83.
Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol 2014;11:255–65.
Libby P, Tabas I, Fredman G, et al. Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res 2014;114:1867–79.
Fang L, Moore XL, Dart AM, et al. Systemic inflammatory response following acute myocardial infarction. J Geriatr Cardiol 2015;12:305–12.
Stefanadis C, Antoniou CK, Tsiachris D, et al. Coronary Atherosclerotic Vulnerable Plaque: Current Perspectives. J Am Heart Assoc 2017;6:e005543doi: 10.1161/JAHA.117.005543.
doi: 10.1161/jaha.117.005543
Ferencik M, Mayrhofer Th, Puchner B, et al. Computed tomography-based high-risk coronary plaque score to predict acute coronary syndrome among patients with acute chest pain – Results from the ROMICAT II trial. J Cardiovasc Comput Tomogr 2015;9:538–45.
Newby AC. Metalloproteinases and vulnerable atherosclerotic plaques. Trends Cardiovasc Med 2007;17:253–8.
Newby AC. Metalloproteinases promote plaque rupture and myocadial infarction: a persuasive concept waiting for clinical translation. Matrix Biol 2015;44:157–66.
Kondapalli MS, Galimudi RK, Srilatha G, et al. Matrix Metalloproteinases in Coronary Artery Disease: A Review. J Life Sci 2012;4:55–8.
Anzai T. Post-infarction inflammation and left ventricular remodeling: a double-edged sword. Circ J 2013;77:580–7.
Mewton N1, Liu CY, Croisille P, et al. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol 2011;57:891–903.
Mewton N, Liu C, Croisille P. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. JACC 2011;57:891–903.
Grover S, Bell G, Lincoff M, et al. Utility of CMR markers of myocardial injury in predicting LV functional recovery: results from PROTECTION AMI CMR sub-study. Heart Lung Circ 2015;24:891–7.
Khan J, McCann G. Cardiovascular magnetic resonance imaging assessment of outcomes in acute myocardial infarction. World J Cardiol 2017;9:109–33.
Haeck J, Verouden JW, Kuijt W, et al. Comparison of usefulness of N-terminal pro-brain natriuretic peptide as an independent predictor of cardiac function among admission cardiac serum biomarkers in patients with anterior wall versus nonanterior wall ST-segment elevation myocardial infarction undergoing primary. PCI 2010;105:1065–9.